AstraZeneca (AZN) has acquired the global rights to Neurimmune’s drug candidate targeting a condition that can lead to heart failure. The drug candidate, named NI006, is currently in Phase Ib trial. AZN shares rose 1.08% to close at $62.00 on March 2. Through its rare disease unit Alexion, AstraZeneca has been granted worldwide exclusive rights to develop, produce, and commercialize NI006. Alexion has agreed to make an upfront payment of $30 million to Neurimmune.  It has also agreed to make additional milestone payments of up to $730 million to Neurimmune if certain development, regulatory, and commercial targets are met.
https://www.tipranks.com/news/astrazeneca-acquires-neurimmunes-heart-failure-drug-candidate?utm_source=advfn.com&utm_medium=referral